Amy Grogg - Concepedia

Author

Amy Grogg

Janssen (United States)

Also Known As

A Grogg, A. Grogg, Amy Grogg, Amy L Grogg, Amy L. Grogg

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Health Outcomes Solutions (United States)Janssen (Belgium)Sinai Health System

About

Amy Grogg is an author at Janssen (United States) specializing in medicine, psychiatry, and psychopathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	239
2	Public Health	2	2	118
3	Social Sciences	2	2	88
4	Diabetes	1	1	62
5	Family Medicine	1	1	11

Amy Grogg

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia Peter J. Weiden, Chris M Kozma, Amy Grogg, Psychiatric Services	2004	621
Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 Diabetes Frank D. Gianfrancesco, Amy Grogg, Ramy Mahmoud, The Journal of Clinical Psychiatry	2002	237
Assessment of compliance with antipsychotic treatmentand resource utilization in a medicaid population Michael Eaddy, Amy Grogg, Julie Locklear Clinical Therapeutics Psychiatric EvaluationCommunity Mental HealthPsychiatryHealth PolicyMedicaid Population	2005	107
An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Muta M. Issa, Thomas C Fenter, Libby Black, PubMed	2006	80
Comparative Study of the Development of Diabetes Mellitus in Patients Taking Risperidone and Olanzapine Matthew A. Fuller, Kenneth M. Shermock, Michelle Secic, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2003	73
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders Frank D. Gianfrancesco, Amy Grogg, Ramy Mahmoud, Clinical Therapeutics Antipsychotic AgentsPsychiatryMedicinePsychotropic MedicationDiabetes	2003	62
Antipsychotics, Glycemic Disorders, and Life-Threatening Diabetic Events: A Bayesian Data-Mining Analysis of the FDA Adverse Event Reporting System (1968-2004) William DuMouchel, David Fram, Xionghu Yang, Annals of Clinical Psychiatry	2008	41
Identifying Patients with Gastroesophageal Reflux Disease: Validation of a Practical Screening Tool Joshua J. Ofman, Michael J. Shaw, Kay Sadik, Digestive Diseases and Sciences	2002	40
Antipsychotic maintenance in schizophrenia: Partial compliance and clinical outcome John P. Docherty, Ramy Mahmoud, Amy Grogg, Schizophrenia Research PsychiatryPsychotic DisorderPsychotropic MedicationPartial ComplianceSchizophrenia	2003	33
Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model Montserrat Vera‐Llonch, Thomas E. Delea, Erin Richardson, Value in Health PsychiatryPsychotic DisorderAddictionPsychotropic MedicationPsychopharmacology	2004	26

Page 1